Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ApnimedAPMD +5.99%8 Days Payable is 362.21 as of Jun. 2026, which is 35% above its 10-year median of 267.45. GuruFocus rates APMD with a GF Score™ of 8/100. Among 707 Biotechnology companies, Apnimed ranks better than 56.01% on this metric.
Apnimed's average Accounts Payable for the
three
months ended in Jun. 2026 was $4.80 Mil. Apnimed's Cost of Goods Sold for the
three
months ended in Jun. 2026 was $1.21 Mil.
Hence, Apnimed's Days Payable for the
three
months ended in Jun. 2026 was 362.21.
The historical rank and industry rank for Apnimed's Days Payable or its related term are showing as below:
APMD'
s Days Payable Range Over the Past 10 Years
Min: 146.49 Med: 267.45 Max: 388.4
Current: 146.49
During the past 2 years, Apnimed's highest Days Payable was 388.40. The lowest was 146.49. And the median was 267.45.
APMD's Days Payable is ranked better than 56.01% of 707
companies
in the Biotechnology industry
Industry Median: 111.24
vs APMD: 146.49
Apnimed's Days Payable
increased
from . 20 (0.00) to Jun. 2026 (362.21).
It may suggest that Apnimeddelayed paying its suppliers.
The historical data trend for Apnimed's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apnimed Days Payable Chart
Apnimed Annual Data
Trend
Dec24
Dec25
Days Payable
416.30
146.49
Apnimed Quarterly Data
Mar25
Jun25
Mar26
Jun26
Days Payable
0.00
0.00
127.07
362.21
APMD vs SANA, CRVS, ODTX: Days Payable Comparison
For the Biotechnology subindustry, Apnimed's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apnimed Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apnimed's Days Payable distribution charts can be found below:
* The bar in red indicates where Apnimed's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Apnimed's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apnimed (APMD) has a Days Payable of 362.21 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Apnimed and its competitors. This is 35% above median its historical median of 267.45. Over the past decade, Apnimed's Days Payable has ranged from 146.49 to 388.40. According to the industry distribution chart, Apnimed ranks #311 out of 707 companies in the Biotechnology industry, placing it in the top 44%.
Is Apnimed's Days Payable too high?
Apnimed's current Days Payable of 362.21 is 35% above median its 10-year median of 267.45. Over the past 10 years, this metric has ranged from a low of 146.49 to a high of 388.40. The Biotechnology industry median Days Payable is 111.24. Apnimed's value of 362.21 is 225.6% above this industry median. Based on the distribution chart, Apnimed ranks #311 out of 707 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Apnimed has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Apnimed's Days Payable compare to SANA and CRVS?
According to the Biotechnology industry distribution chart, Apnimed ranks #311 out of 707 companies for Days Payable. This puts Apnimed in the upper half of its industry. The industry median Days Payable is 111.24. Apnimed's value of 362.21 is 225.6% above this benchmark. Historically, Apnimed's own Days Payable has ranged from 146.49 to 388.40 over the past decade. While the company's 10-year median is 267.45 vs. the industry median of 111.24, Apnimed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.24, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apnimed's current Days Payable of 362.21 is 225.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Apnimed and its competitors. For the Biotechnology industry, the median Days Payable is 111.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apnimed's current Days Payable is 362.21, which is 35% above median its own 10-year median of 267.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apnimed stock overvalued right now?
Apnimed (APMD) has a current Days Payable of 362.21. The current Days Payable is 362.21, which is 35% above median its 10-year median of 267.45 and 225.6% above the Biotechnology industry median of 111.24. Apnimed's overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Apnimed (APMD), the current Days Payable is 362.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
8GF Score
Get the complete analysis for APMD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APMD has been successfully added to your 
